📊 CLB Key Takeaways
Investment Thesis
Core Laboratories demonstrates solid financial health with strong liquidity (2.37x current ratio) and manageable leverage (0.43x debt/equity), but profitability metrics reveal concerning trends including declining net income (-2.3% YoY), compressed diluted EPS (-14.3% YoY), and modest net margins of 6.4%. Revenue growth of only 2.8% YoY coupled with declining earnings quality suggests the company is facing cyclical headwinds typical of oil & gas services, warranting a cautious stance until margin expansion is demonstrated.
CLB Strengths
- Strong liquidity position with 2.37x current ratio and 1.76x quick ratio, indicating solid short-term solvency
- Conservative leverage with 0.43x debt/equity ratio and adequate interest coverage of 5.1x, reducing financial distress risk
- Positive free cash flow generation of $20.8M with 5.4% FCF margin, supporting dividend capacity and debt service
CLB Risks
- Declining profitability with net income down 2.3% YoY and diluted EPS down 14.3% YoY, indicating earnings pressure
- Anemic revenue growth of 2.8% YoY with modest 6.4% net margin, suggesting limited pricing power or volume challenges
- Low returns on equity (9.1%) and assets (4.2%) indicate capital is not being deployed efficiently relative to sector peers
Key Metrics to Watch
- Operating margin trend and revenue growth acceleration in next quarters
- Free cash flow sustainability and capital deployment decisions
- Debt/equity ratio and interest coverage ratios to ensure financial flexibility
CLB Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.37x current ratio provides a solid financial cushion.
CLB Profitability Ratios
CLB vs Energy Sector
How Core Laboratories Inc. /DE/ compares to Energy sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLB Balance Sheet & Liquidity
CLB 5-Year Financial Trend
5-Year Trend Summary: Core Laboratories Inc. /DE/'s revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $0.42 reflects profitable operations.
CLB Growth Metrics (YoY)
CLB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $134.4M | $11.7M | $0.25 |
| Q2 2025 | $130.2M | $9.0M | $0.19 |
| Q1 2025 | $123.6M | -$154.0K | $0.00 |
| Q3 2024 | $125.3M | $9.3M | $0.19 |
| Q2 2024 | $127.9M | $9.0M | $0.19 |
| Q1 2024 | $128.4M | $2.4M | $0.05 |
| Q3 2023 | $125.3M | $7.5M | $0.16 |
| Q2 2023 | $120.9M | $5.2M | $0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CLB Capital Allocation
CLB SEC Filings
Access official SEC EDGAR filings for Core Laboratories Inc. /DE/ (CIK: 0001958086)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLB
What is the AI rating for CLB?
Core Laboratories Inc. /DE/ (CLB) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLB's key strengths?
Strong liquidity position with 2.37x current ratio and 1.76x quick ratio, indicating solid short-term solvency. Conservative leverage with 0.43x debt/equity ratio and adequate interest coverage of 5.1x, reducing financial distress risk.
What are the risks of investing in CLB?
Declining profitability with net income down 2.3% YoY and diluted EPS down 14.3% YoY, indicating earnings pressure. Anemic revenue growth of 2.8% YoY with modest 6.4% net margin, suggesting limited pricing power or volume challenges.
What is CLB's revenue and growth?
Core Laboratories Inc. /DE/ reported revenue of $388.3M.
Does CLB pay dividends?
Core Laboratories Inc. /DE/ pays dividends, with $1.4M distributed to shareholders in the trailing twelve months.
Where can I find CLB SEC filings?
Official SEC filings for Core Laboratories Inc. /DE/ (CIK: 0001958086) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLB's EPS?
Core Laboratories Inc. /DE/ has a diluted EPS of $0.52.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.